Cocrystal Pharma, Inc. (NASDAQ:COCP) Stock Short Interest Report for September

Cocrystal Pharma, Inc. (NASDAQ:COCP) saw a significant decrease in short interest in September. As of September 30th, there was short interest totaling 175,246 shares, a decrease of 45.7% from the September 15th total of 322,748 shares. Based on an average daily trading volume, of 54,337 shares, the days-to-cover ratio is currently 3.2 days. Currently, 1.5% of the company’s shares are sold short.

Wall Street Analyst Weigh In

Several brokerages have commented on COCP. HC Wainwright reiterated a “buy” rating on shares of Cocrystal Pharma in a report on Friday. Weiss Ratings lowered shares of Cocrystal Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 21st. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold”.

Cocrystal Pharma Stock Down 2.3%

Shares of COCP traded down $0.03 during mid-day trading on Wednesday, reaching $1.05. The company’s stock had a trading volume of 2,801 shares, compared to its average volume of 815,898. The company has a market cap of $20.32 million, a price-to-earnings ratio of -1.39 and a beta of 1.48. The business has a fifty day moving average of $1.13 and a 200 day moving average of $1.14. Cocrystal Pharma has a 1 year low of $0.76 and a 1 year high of $2.03.

Cocrystal Pharma (NASDAQ:COCP) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.06). The firm had revenue of $0.11 million during the quarter, compared to analyst estimates of $0.10 million. On average, analysts predict that Cocrystal Pharma will post -0.69 earnings per share for the current year.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc is a clinical-stage biotechnology company focused on discovering and developing antiviral therapies. The company uses a structure-based drug discovery platform to identify small-molecule compounds designed to interfere with essential viral replication proteins.

Its research programs have targeted a range of viral diseases, including influenza A, norovirus and coronaviruses. Cocrystal’s development activities have included orally administered antiviral candidates intended for the treatment or prevention of viral infections, with programs advancing through a combination of preclinical research and clinical development.

Founded in 2007 and formerly known as BioZone Pharmaceuticals, the company adopted the Cocrystal Pharma name after combining with Cocrystal Discovery in 2015.